Search results for "Prognostic"

showing 10 items of 316 documents

Evaluation of c-erbB-2-oncogene expression as a prognostic factor in ovarian cancer

1995

OncologyCancer Researchmedicine.medical_specialtyPrognostic factorHematologybusiness.industryGeneral MedicineC erbb 2 oncogenemedicine.diseaseOncologyInternal medicinemedicineOvarian cancerbusinessJournal of Cancer Research and Clinical Oncology
researchProduct

In the literature: October 2020.

2020

Immune checkpoint inhibitors are widely used as treatment for an increasing number of solid tumours. Nevertheless, the lack of predictive biomarker represents a limitation across several cancer types. During the last years, the possibility to dynamically study tumour evolution through circulating tumour DNA (ctDNA) in plasma has opened novel possibility in evaluating disease status and therapeutic response, especially in localised disease to predict the possibility of relapse. However, the specific opportunities for application in the context of immunotherapy remain to be clarified.1 In an article recently published in Cancer Discovery by Zhang et al ,2 a comprehensive analysis of ctDNA dat…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableDurvalumabbusiness.industryCancerMicrosatellite instabilityContext (language use)DiseaseNewsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282not applicableOncologyInternal medicinemedicine1506Lung cancerbusinessTremelimumabmedicine.drugESMO open
researchProduct

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

2014

Abstract Purpose: FcγR polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableGenotypeColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicineGenotypemedicineHumansGenotypingCetuximabProportional hazards modelbusiness.industryReceptors IgGPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyImmunologyColorectal NeoplasmsbusinessAdjuvantChemoradiotherapymedicine.drugClinical Cancer Research
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

2016

Purpose Identifying patients at high risk of progression and early death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models. This study aimed to determine the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [18F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18F]FDG/PET-CT) scans and its added value to these models. Patients and Methods A pooled analysis was performed by using patient data and centrally reviewed baseline PET-CT scans for 185 patients with FL who were receiving immunochemotherapy within three prospective trials. TMTV was computed by using the 41% maximum st…

OncologyFluorodeoxyglucoseCancer Researchmedicine.medical_specialtybusiness.industryFollicular lymphomaStandardized uptake valueMetabolic tumor volumemedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePooled analysisInternational Prognostic IndexOncology030220 oncology & carcinogenesisInternal medicineMedicinePositron emissionStage (cooking)businessNuclear medicinemedicine.drugJournal of Clinical Oncology
researchProduct

Using Cox's proportional hazards model for prognostication in carcinoma of the upper aero-digestive tract.

1992

One of the major short comings of the traditional TNM system is its limited potential for prognostication. With the development of multifactorial analysis techniques, such as Cox's proportional hazards model, it has become possible to simultaneously evaluate a large number of prognostic variables. Cox's model allows both the identification of prognostically relevant variables and the quantification of their prognostic influence. These characteristics make it a helpful tool for analysis as well as for prognostication. The goal of the present study was to develop a prognostic index for patients with carcinoma of the upper aero-digestive tract which makes use of all prognostically relevant var…

OncologyLarynxAdultMalePrognostic variablePathologymedicine.medical_specialty03 medical and health sciencesMultifactorial analysis0302 clinical medicineSurvival dataInternal medicinemedicineCarcinomaHumansBasal cell030223 otorhinolaryngologyAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overHypopharyngeal NeoplasmsProportional hazards modelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival Ratestomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisCarcinoma Squamous CellDigestive tractFemaleMouth NeoplasmsbusinessActa oto-laryngologica
researchProduct

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

2020

[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).

OncologyMaleCancer Researchmedicine.medical_specialtyNeoplasm ResidualDiseaseResidualTHERAPYDexamethasoneFlow cytometryBortezomib03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMeaning (existential)Longitudinal StudiesLenalidomideMultiple myeloma030304 developmental biologyCONSOLIDATIONRandomized Controlled Trials as Topic0303 health sciencesCOMPLETE RESPONSEmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseFlow Cytometry3. Good healthClinical trialPROGNOSTIC VALUEbody regionsMRDOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisFemaleSTEM-CELL TRANSPLANTbusinessMultiple MyelomaDARATUMUMABJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

2021

Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-u…

OncologyMaleSurvivalHepatocellular carcinomaCohort study Hepatocellular carcinoma Prognosis Sorafenib SurvivalSeverity of Illness IndexAntineoplastic Agent0302 clinical medicineProspective StudiesLiver NeoplasmsGastroenterologyMiddle AgedSorafenibPrognosisTreatment OutcomeItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleLiver cancerCohort studymedicine.drugCohort studySorafenibCohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; Survivalmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIAAntineoplastic AgentsRisk Assessment03 medical and health sciencesInternal medicinemedicineHumansneoplasmsPrognostic modelsNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGold standardmedicine.diseasedigestive system diseasesMulticenter studybusiness
researchProduct

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergr…

2022

Abstract Background: The management of melanoma patients with metastatic sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients. Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Overall survival (OS) was the outcome of interest; included independent variables were the following: age, gender, primary melanoma site, Breslow thickn…

OncologyMaleTreatment of cutaneous melanomamedicine.medical_specialtyCompletion lymph node dissectionSkin NeoplasmsCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burden; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Tumor Burden; Lymphadenopathy; Melanoma; Sentinel Lymph Node; Skin NeoplasmsTumor burdenSettore MED/19 - Chirurgia PlasticaLymphadenopathyPrognostic factorsNomogramInternal medicineBiopsymedicineMetastatic melanoma in the sentinel nodesHumansCLNDOverall survivalMelanomaCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burdenRisk stratificationRetrospective Studiesmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyMelanomaTumor burdenSentinel nodemedicine.diseasePrognosisLymphatic MetastasisLymph Node ExcisionSentinel Lymph Nodebusiness
researchProduct